Patient Test Information


This IMA test was developed to measure the amount of ischemia-modified albumin (IMA) in the blood. However, the test was never widely used and is no longer available for clinical use in the U.S. IMA was thought to be a promising cardiac biomarker, and a version of the test was approved by the FDA to help rule out cardiac ischemia in people with chest pain whose diagnosis was not clear. It was always ordered along with or following a troponin test and an ECG to provide the doctor added information if the initial troponin test was negative and the ECG was not definitive. Though this test is no longer available for use in patient care, some scientists continue to study IMA in research settings.